Dynacure secures $55M as their Ionis-developed drug moves into clinic
A month after dosing their first ever patient with their Ionis-licensed tech, Dynacure has announced a new round of funding to advance the trial.
The French biotech announced €50 million ($55 million) in Series C funding, led by Perceptive Advisors. Although listed as a Series C, it is the second tranche of cash the company has ever announced, after their initial $55 million raise in 2018. The cash will float Dynacure through its Phase I/II trial in a class of neuromuscular diseases known as myotubular and centronuclear myopathies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.